NGM Biopharmaceuticals, a Phase 2 biotech developing therapies for NASH and type 2 diabetes, raised $107 million by offering 6.7 million shares at $16, the high end of the range of $14 to $16. NGM Biopharmaceuticals plans to list on the Nasdaq under the symbol NGM. Goldman Sachs, Citi and Cowen acted as lead managers on the deal.
NASH biotech NGM Biopharmaceuticals prices IPO at $16, the high end of the range
April 3, 2019

